Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.5906
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 143953568400.0
- FreeCF/Share 1.9771
- PFCF 12.8301
- PE 18.2674
- Debt/Assets 0.2946
- DivYield 0.0671
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Is Pfizer Stock a Buy?
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative
Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.
Read More
2 Absurdly Cheap Stocks to Buy and Hold for Years
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.
Read More
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Read More
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
Published: April 02, 2025 by: Reuters
Sentiment: Negative
Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
Published: March 26, 2025 by: New York Post
Sentiment: Negative
The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.
Read More
Here's Why Pfizer (PFE) Fell More Than Broader Market
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Read More
5 Large Drug Stocks to Watch as Industry Recovers
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Industry Description
Read More
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Of late, pharmaceutical behemoth Pfizer Inc.'s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren't in bad shape either.
Read More
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.
Read More
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (PFE -0.50%). The pharmaceutical giant isn't as risky an investment as it may appear to be.
Read More
Pfizer to dispose of entire Haleon stake
Published: March 18, 2025 by: Reuters
Sentiment: Neutral
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
Read More
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
Published: March 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.
Read More
3 High-Yield Dividend Stocks to Buy Before March Ends
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
These three dividend stocks are certainly worth considering for long-term investors seeking higher yields in this declining interest rate environment.
Read More
Calls of the Day: Invitation Homes, Pfizer and Roblox
Published: March 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Published: March 11, 2025 by: Benzinga
Sentiment: Negative
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.
Read More
Pfizer: Undervalued Safe Haven In Risk-Off Market
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expectations of 9%-11%. R&D pipeline advanced with 12 approvals, 7 pivotal study starts, and 8 Phase 3 readouts, boosting oncology and obesity treatments.
Read More
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Read More
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
Read More
Pfizer appoints James List to lead development of obesity medicines
Published: March 06, 2025 by: Reuters
Sentiment: Positive
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.
Read More
Final Trades: Pfizer, Paychex and the JEPI
Published: March 06, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debates their Final Trades.
Read More
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. "Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted …
Read More
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
Published: February 24, 2025 by: Reuters
Sentiment: Positive
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Read More
Pfizer: What The Summit Therapeutics Deal Brings
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer: What The Summit Therapeutics Deal Brings
Read More
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Read More
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Published: February 23, 2025 by: The Motley Fool
Sentiment: Positive
Buying quality stocks when they're unpopular can be very rewarding.
Read More
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Published: February 21, 2025 by: The Motley Fool
Sentiment: Positive
Looking for a good area in which to invest? Consider the healthcare sector.
Read More
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000